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Background: 
results in increased costs for healthcare providers. 
Aim: This review aimed to understand the causes and consequences of medicines nonadherence and 
to suggest effective methods to improve adherence. 
Method:
adherence on health outcomes and healthcare costs. Studies were appraised for their appropriateness 
as evidence using the Critical Appraisal Skills Programme tool. An initi
out on the following databases: 
sources were used (systemic reviews, trials, reports, studies) and a further 6 sources were used to 
provide definitions.
Conclusion: 
relationship between intentional and unintentional nonadherence among different patient groups, 
conditions and types of treatment
understand patient beliefs about and their medication adherence barriers; the financial cost of 
medicines nonadherence and 
professions
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INTRODUCTION 
 
Medicines adherence is defined as the “extent to which a 
patient’s behaviour matches the treatment plan
adherence is not just related to taking prescribed medications;
the World Health Organization (WHO) states that adherence is 
the “extent to which a person’s behaviour - taking medication, 
following a diet, and/or executing lifestyle changes which 
corresponds with agreed recommendations from a health care 
provider.2”  
 
In healthcare; adherence and compliance are almost used 
interchangeably, but there is a distinct difference between the 
two. Compliance assumes a patient’s passivity (German,1988), 
whilst adherence emphasises an agreement between the patient 
and healthcare provider3. 
 
Nunes1states nonadherence can have two overlapping 
categories; unintentional and intentional. Unintentional 
nonadherence occurs when factors outside of the control of a 
patient prevent adherence; the cost of medications, treatment 
complexity and low health literacy. Intentional nonadherence 
is when a patient actively decides not to follow 
recommendations. Assessing nonadherence starts with an 
understanding of patients’ perspectives of medicines and the 
reasons why they may not want to, or are unable, to use them.
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Low rates of patients adhering to their medications is a major healthcare problem
 
 
 The review focused on studies with primary outcome aimed at the impact of improving 
Cochrane Library, PubMed, BMJ, and NICE. A total of 63 literary 
 The data was interpreted to detect for bias. 
This review highlights the need for further research to 
. There is also need for research that are directly aiming to 
developing models to improve integration between healthcare 
. 
. This is an open access article distributed under the Creative Commons Attribution 
 original work is properly cited.
1”. Lack of 
 
 
It is estimated that 30% to 50% of medications are not t
recommended4. This indicates that behaviour needs to change 
to see improvements. High rates of nonadherence are 
counterproductive when the National Health Service (NHS) 
aims to make efficiency savings of £22 billion by 2020/21
 
METHODOLOGY 
 
A search of the literature included published guidelines, 
systematic reviews, studies, reports and economic evaluations. 
The following databases were searched, in the period between 
November 2017 and March 2018: 
The BMJ, and NICE Evidence Search.
 
Inclusion Criteria: The study described 
aiming to improve medication adherence; adherence was 
measured within the study or adherence outcomes were 
reported. 
 
Exclusion Criteria: (1) papers were written in a language 
other than English; (2) the research within the studies was still 
ongoing; (3) full published versions of the studies were not 
available. 
 
A total of 63 sources were used (systematic reviews, trials, 
reports, studies) and a further 6 sources provided definitions
Table 1 shows the search terms used.
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RESULTS 
 
Unintentional nonadherence 
 
Socioeconomic status 
 
It’s difficult to accurately measure how low socioeconomic 
standing affects compliance with medications. Even the 
definition of socioeconomic deprivation is subject to debate. A 
large study in Sweden looked at this6.It was a cross-sectional 
population-based study of 31, 895 patients aged 21–84 years, 
who had any contact with a physician at a hospital or primary 
care centre. The study found that socioeconomic disadvantage 
was associated with low adherence to medication. This was 
independent of patients having chronic diseases, poor 
education, living alone, risky lifestyle and low approval for 
healthcare providers. Non-adherence was also higher in elderly 
patients, especially elderly women6. 
 
Elderly Patients 
 
Bae7surveyed 201 subjects aged >65 taking antihypertensive 
medications. The subjects were allocated to three groups: (1) 
adherent, (2) unintentional nonadherence and (3) intentional 
nonadherence. The results showed just over 45% of the elderly 
subjects were adherent. However, 48.9% admitted to 
behaviours which fell into the unintentionallynonadherent 
group7.Another study investigated medicines adherence in 
chronic diseases and found elderly people struggle with 
adherence. This was attributed to lack of understanding of drug 
regimens and forgetfulness noting a higher prevalence of 
cognitive problems, multiple pathologies and increased rates of 
polypharmacy8. 
 
Ethnic Minorities 
 
A systematic review looking into adherence influencing 
factors found that belonging to an ethnic minority had a 
consistently negative effect9.  
 
Differences in cultural beliefs, language barriers and lack of 
access to appropriate healthcare were suggested as possible 
reasons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adolescents and Children 
 
A study of adherence rates in children and adolescents with 
Attention Deficit Hyperactivity Disorder (ADHD) found 
nonadherence to medication to be at 19%. The study included 
35 children (aged 6 to 12 years) and 57 adolescents (aged 13 to 
18 years) assessed through a specialist clinic10.Chan et 
al.11looked into medicines adherence in school-aged children 
with asthma and reported that median adherence to asthma 
medications was at 30% (17–48%)for the 101 participants. The 
children had a mean age of 8.9 years. They found that being a 
female or having Asian ethnicity increasedadherence by 12% 
and 19%, respectively. Children who were diagnosed at a 
younger age had adherence increased by nearly 3% for every 
year of age less at diagnosis. However, children in a smaller 
household were found to have decreased adherence to asthma 
medications. Adherence rates in younger people cannot solely 
be based on age; but varies with disease, comorbidities, drug 
regimens, financial situation, social support, side effects to 
medications and parent’s beliefs12. 
 
Health Literacy 
 
Health literacy is defined as “the degree to which individuals 
have the capacity to obtain, process, and understand basic 
health information and services needed to make appropriate 
health decisions13”.Many studies have been conducted to 
determine whether it is a primary cause of nonadherence. 
Geboers et al.14 reviewed17 studies of the impact of health 
literacy as a predictor of medication adherence in adults. There 
was inconsistent evidence concerning causes of low health 
literacy and how it adversely affected adherence to 
medications. The review found vulnerable populations with 
low health literacy may benefit from adherence interventions 
such as improving education and making adherence 
instructions easier to understand15. For example, a patient may 
decide not to take a medication for reasons not connected with 
the patient not knowing how to take it through low health 
literacy. Also, the criteria used to determine health literacy 
vary significantly so comparison is difficult16. 
 
Nevertheless, research suggests patients do require a basic 
level of health literacy. A meta-analysis of 220 articles found 
Table 1 showing the search terms used to generate results on databases 
 
Search terms used 
Results from 
Cochrane Library 
Results from 
PubMed 
Results from The 
BMJ 
Results from NICE 
Evidence Search 
Unintentional + Adherence 1 217 154 327 
Socioeconomic + Adherence 3 3822 481 1 
Elderly + Adherence 3 39866 2800 2076 
Ethnic minority + Adherence 3 556 249 839 
Adolescent + Adherence 33 13898 1810 2518 
Children + Adherence 75 14841 14739 4490 
Health literacy + Adherence 4 832 86 640 
Social support + Adherence 11 6337 15226 4267 
Drug regimen + Adherence 39 7282 1234 2144 
Disease + Adherence 116 32631 24816 8332 
Recalling information + 
Adherence 
3 188 2227 60 
Prescription cost + Adherence 4 1712 1578 1886 
Prescribing + Adherence 44 3581 6745 3779 
Communication + Adherence 18 8509 14409 4740 
Intentional + Adherence 3 263 5675 348 
Beliefs + Adherence 5 10164 4875 1751 
Health + Adherence 170 61950 20996 10921 
Healthcare Costs + Adherence 34 6037 1025 3627 
Causes + Adherence 67 45565 23233 5156 
Behaviour + Adherence 62 43916 3218 4392 
Interventions + Adherence 193 22649 4328 8485 
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that health literacy interventions increased adherence, 
especially among vulnerable patient groups17. 
 
Social Support 
 
A meta-analysis conducted by DiMatteo18 found adherence 
“1.74 times higher in patients from cohesive families and 1.53 
times lower in patients from families in conflict.” Being 
married and not living alone modestly increased adherence. 
Twenty-nine of the studies analysed focused on practical 
support. Adherence rates were 3.6 times higher in patients who 
received practical support. Patients who received no support 
had approximately double the risk of becoming non-adherent. 
Social support it appears has a positive effect on, but it is 
difficult to judge its effectiveness between different diseases. 
 
Patient Drug Regimens 
 
There is growing evidence that the more complex the drug 
regimen, the less likely a patient is to be adherent. A 
systematic review examining the association between dose 
regimen and medication compliance found that the prescribed 
number of doses per day was inversely related to adherence. 
Adherence rates were much higher for once daily-dosing 
compared to multiple daily dosing regimens19. Another 
systematic review of 38 randomised controlled trials looked at 
adherence with antihypertensive medications. Reducing the 
number of daily doses was effective in increasing adherence. 
Simplifying regimens increased adherence in 7 of the 9 
studies, with a relative increase in adherence of 8% to 19.6%20.  
 
Diseases 
 
WHO stated that in general “adherence rates are higher among 
patients with acute conditions compared to patients with 
chronic diseases2.” A study observing adherence to statin 
therapy in elderly patients with and without acute coronary 
syndromes over a two year period, found adherence rates to be 
at 40.1% for patients with acute coronary syndrome and 36.1% 
for patients with chronic coronary artery disease21. Another 
study of 34,501 participants found adherence rates of patients 
receiving long-term HMGCoA reductase therapy to be at 60%, 
43%, 26%, and 32% after 3, 6, 60, and 120 months, 
respectively22.  
 
A cross-sectional study of 633 participants, which measured 
adherence among patients affected by chronic diseases 
(hypertension, diabetes, and chronic obstructive pulmonary 
disease) found that just over 39% of patients reported 
themselves adherent across a period of 4 weeks23. However, a 
study looking into the factors influencing compliance with 
long-term antiepileptic drug regimens found adherence 
relatively high. Out of 696 epileptic patients, 95% were taking 
their antiepileptic drugs (AEDs). Of this 95%, over 70% of 
patients did not miss a dose, 15% of patients missed <1 dose a 
month and 9% missed a >1 dose in a month. Under 5% of 
patients missed a dose at least once a week24. Most of the 
studies reviewed revealed that adherence rates are generally 
lower in patients suffering from chronic conditions21-23. Many 
of the causes for low adherence in chronic conditions relate to 
the specific diseases e.g. side effects, cost , lacking knowledge 
of the treatment, regimen complexity, patient’s beliefs, 
depression, poor communication from treatment provider and 
lack of access to appropriate healthcare2.  
 
 
 
Recalling Information 
 
Linn, examined the relationship between recall of medical 
information and adherence in patients with inflammatory 
bowel disease (IBD)25. The study (n=68) found that only 
52.6% recalled the information they were given immediately 
after a consultation and 53.8% after three weeks. The 
consultations were recorded, and patients surveyed 
immediately after consultation and after three weeks. Jansen 
studied 260 patients with heterogeneous cancers, finding that 
younger and older patients correctly recalled 49.5% and 48.4% 
of the information they were provided, respectively26. Poor 
recall is also correlated with reduced adherence rates in 
Chronic Obstructive Pulmonary Disease27 and Human 
Immunodeficiency Virus infection28. 
 
Prescription Costs 
 
For England, in 2013, over 90% of all prescription items were 
dispensed free of charge. The majority of these (64.2%) were 
age exemptions29. A study exploring the non-dispensing of 
NHS prescriptions in community pharmacies (n=514) found 
cost‐related reasons for not presenting prescriptions for 
dispensing included the availability of cheaper 
over‐the‐counter (OTC) products (78.6%) and incidents of 
customers unwilling or unable to pay the prescription charge 
(20.1%). Consequent upon this, 242 OTC products were sold, 
97.0% of which contained the same active ingredient as the 
prescription item. There were 62 incidents where a prescribed 
item was not dispensed, or substituted, because of cost, and 
more than one‐third would be considered to be clinically 
important30. A report prepared by WHO noted the effect of 
prescription charges differs between groups of patients; it 
noted that the “implementation of full coverage of free 
prescriptions appeared to be associated with a greater increase 
in the use of medicines by those with a lower health status31”.  
 
Healthcare Professionals (communication and prescribing)  
 
Effective communication can produce a positive effect32. In 
1998, the American Academy of Orthopaedic Surgeons 
surveyed 807 patients and 700 orthopaedic surgeons. An 
interesting difference was found in how the surgeons perceived 
their communication with patients compared to how their 
patients perceived them. Three-quarters of the surgeons 
believed they communicated satisfactorily but most patients 
felt communication was not satisfactory. Only 21% of patients 
deemed the communication satisfactory33. Another study 
looked at patient and provider factors in the lack of adherence 
in type 1 and type 2 diabetes. The 367 patients were assessed 
for level of adherence to treatment, depression, attachment and 
disease severity. Adherence to medications and glucose 
monitoring was significantly worse in patients who rated their 
patient-provider communication as poor34.  
 
A questionnaire-based study of the appropriateness of 
prescribing in general practice within England included 24 
general practitioners and 186 patients who completed 
questionnaires before and after consultations35. Phone 
interviews were then conducted one week after their 
consultations. The results from the questionnaires showed that 
31% of prescriptions were either not wanted by the patients, 
were technically inappropriate or the prescriber thought they 
were not strictly indicated. The telephone interviews revealed 
18%of patients were potentially non-adherent (had not started 
taking their medicine, had stopped early, had missed doses, or 
had altered the dosages). Results from a collaborative audit of 
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pharmacy-led medicine reconciliations in 56 NHS trusts across 
England, showed that when admitted most patients have a 
medicine omitted (73%) or a wrong dose recorded (14%). 
Patients on multiplelong-term medications were most likely to 
have errors. These results came from 8621 medicines 
reconciliations covering 49,099 medicatons23.  
 
Intentional nonadherence 
 
Intentional nonadherence is influenced by a patients’ beliefs.  
It includes those who do not take their medicines at all 
(absolute noncompliance) and those who alter the dose or 
frequency of their medicines or only take the treatment as 
perceived necessary (Horne et al. 2005). A meta-analysis of 94 
studies covering 24 long-term conditions involving 25,072 
patients from multiple countries showed the decision to take a 
medicine is decided by individual perceptions of the need for 
the medicine (necessity beliefs) and concerns about potential 
adverse consequences of taking it. Patients believing their 
treatment necessary and those with fewer concerns about their 
treatment had higher adherence. The study concluded that 
accounting for necessity beliefs and concerns enhanced the 
quality of prescribing by helping clinicians to engage patients 
in treatment decisions and support optimal adherence36. 
Poundet al.37, conducted a meta-analysis of 37 qualitative 
studies and found similar results to Horne36. Patients don’t 
adhere to medications correctly because of concerns about the 
medicines themselves (adverse drug reactions, lay evaluation 
of medicines) and those on long-term treatments test their 
requirement through dose alteration or trial cessation. Patients 
appear reluctant to take medicines and prefer to take as few as 
possible. 
 
A United Kingdom study (n=161) found 34% of patients were 
taking their medicine differently to that prescribed, through a 
conscious decision. The two most frequent reasons were; side 
effects and adjustment of the regimen in response to 
symptoms38. Sjölander, Eriksson and Glader39 conducted a 
cross-sectional questionnaire completed by 595 stroke patients 
to find out about patients’ beliefs on stroke and drug treatment 
and their adherence to drug treatment. Of the patients 12.5% 
were classified as non-adherent. A significant number of non-
adherent patients scored lower on positive beliefs about 
medicines and higher on negative beliefs.  
 
Gagnon et al. surveyed 343 participants about whether beliefs 
about their medications had a greater impact on adherence 
compared to other barriers (cost, access, forgetting to get 
refills, transportation, hospitalisation)40. Patients reporting 
more negative beliefs towards their medicines were 49% less 
likely to adhere, whilst barriers to adherence showed no 
significant.  
 
Effect of adherence on health outcomes 
 
Poor adherence is associated with a poor glycaemic control in 
type two diabetics41,42, whilst higher adherence gives better 
glycaemic control43-45. Type 2 diabetics with poor adherence to 
diet and exercise show decreased glycaemic control46. In 
patients who already have glucose intolerance, adherence to a 
low-fat diet improves body weight and glucose tolerance over 
2-3years47.  
 
Low adherence to antihypertensives has been associated with 
poor blood pressure control48. Patients with high adherence 
were around five times more likely to have controlled blood 
pressure when compared to patients with low adherence49. It 
was also associated with significantly higher risk of stroke50. A 
study by Alhalaiqa, et al.investigated adherence therapy (AT) 
compared with treatment as usual (TAU) in reducing blood 
pressure in noncompliant hypertensive patients51. There were 
136 non-adherent participants; 68 patients received TAU and 
68 AT. Systolic blood pressure was reduced in the AT group 
by 23.11 mmHg more than in the TAU group and similarly, 
diastolic blood pressure was by 15.18mmHg more than in the 
TAU group at 11 weeks. Adherence was measured by pill 
counting and was improved by 37% in the AT groupat 11 
weeks. 
 
A randomised controlled trial found adherence to selective 
serotonin reuptake inhibitors or tricyclic antidepressants had a 
positive impact on treatment; irrespective of the antidepressant 
used52. Sirey, Bruce and Kales examined the effectiveness of a 
psychosocial intervention to improve antidepressant adherence 
and depression outcomes53. The group that had the 
psychosocial intervention (Treatment Initiation and 
Participation Program) was significantly more adherent to their 
antidepressant pharmacotherapy and had a significantly greater 
decrease in depressive symptoms compared to controls. Sokol, 
et al. studied the impact medication adherence had on 
hospitalisation risk in137,277 patients (diabetes, hypertension, 
hypercholesterolemia or congestive heart failure) who were 
observed over the course of 23 months54. Across all four 
conditions, patients that maintained high adherence to 
medications (between 80-100%) were significantly less likely 
to be hospitalised. 
 
Adherence and Healthcare Costs 
 
Finding data on the impact adherence has on healthcare costs 
is challenging. Trueman et al. attempted to explore the 
economic impact of poor adherence on NHS finances, 
examining long-term conditions (asthma; type 2 diabetes; high 
cholesterol/coronary heart disease; statins for primary 
prevention and secondary prevention; hypertension; and 
schizophrenia)55. For each condition, they assessed whether 
non-compliance had a material impact on health. The results 
were provided in the form of quality-adjusted life years 
(QALYs- valued at £20, 000). They concluded if all patients 
were fully compliant with medications, savings would be £930 
million per year, for the five conditions: 
 
 “Asthma£130 million 
 Type 2 Diabetes£100 million 
 High cholesterol/ CHD£120 million 
 Hypertension£390 million 
 Schizophrenia£190 million”55 
 
The methods and assumptions used in this study are open to 
question but highlight the scale of the impact of nonadherence 
on healthcare finances.  
 
Strategies to improve adherence 
 
The scale of the problem 
 
Haynes et al. stated current methods for improving adherence 
for chronic health problems are mostly complex and not very 
effective, resulting in suboptimal treatment56. 
 
A Cochrane review by Nieuwlaat et al., looked into effective 
interventions to improve medication adherence57. From >100 
randomised controlled trials (RCTs), the review found only 5 
RCTs reported improvement in both adherence and outcomes. 
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Between the 5 RCTs, no common intervention characteristics 
were apparent.  
 
Potential solutions 
 
To date, no known interventions lead to major improvements 
in adherence and clinical outcomes. However, some have 
found positive findings. Emerging strategies are signposting 
possible ways forward. 
 
Understanding patient beliefs 
 
Healthcare professionals must understand a patient’s beliefs 
about their medications. Horne et al. reported a “patient's 
decision to take a medicine is often a balance between their 
perceptions of the personal need for the medicine (necessity 
beliefs) and concerns about potential adverse consequences of 
taking it.36” These concerns are deeply rooted in a patient’s 
psyche and relate to concerns about dependency and fears 
about negative effects of long-term medication use. Personal 
beliefs, previously negative experiences with medications, 
listening to the experiences of others and misinformation were 
all factors that were shown to influence these concerns. They 
concluded that such an understanding could help promote 
medications adherence and engage patients in treatment 
decisions.  
 
A conceptual model called the Necessity-Concerns Framework 
(NCF) was created to help healthcare professionals with this 
issue. The NCF postulates that “adherence is influenced by 
implicit judgements of personal need for the treatment 
(necessity beliefs) and concerns about the potential adverse 
consequences of taking it36”. The framework has been shown 
to be a useful tool in assessing what a patient thinks about their 
medications58-60.  
 
Patient Behaviour  
 
Understanding the causes of nonadherence and then having the 
appropriate behavioural tools to implement tailored adherence 
interventions could be one way forward. The Theoretical 
Domains Framework (TDF) was compiled from 33 theories 
and 128 key theoretical constructs related to behavioural 
change. They were synthesised into a single framework to 
allow easier assessment of behavioural problems and helps 
create effective interventions. The aim was to simplify and 
integrate the many behaviour change theories and make the 
them accessible to, and usable by, other disciplines61. The 
Theoretical Domains Framework (TDF) is composed of “14 
theoretical domains: 
 
1. Knowledge 
2. Skills 
3. Social/Professional Role and Identity 
4. Beliefs about Capabilities 
5. Optimism 
6. Beliefs about Consequences 
7. Reinforcement 
8. Intentions 
9. Goals 
10. Memory/Attention/Decision Processes 
11. Environmental Context and Resources 
12. Social Influences 
13. Emotion 
14. Behavioural Regulation”61. 
 
The COM-B model (Capability, Opportunity, Motivation-
Behaviour) requires a person to have the adequate capability, 
opportunity, and motivation for a behaviour (such as adhering 
to medications) to take place. If there are deficits in any one of 
these areas, the behaviour is unlikely to occur62. 
 
TheTDF and COM-B models are closely linked; both allow 
determinants of behaviours (such as medicines-taking), to be 
explored in more depth than the binary model of intentional 
and unintentional non-adherence, allowing the actual cause for 
non-adherence to be determined63. Advantages from using the 
models are that both were created using evidence-based 
behaviour change techniques61,62. This allows for adherence 
barriers to be linked with evidence-based behaviour change 
techniques, which helps patients to overcome their adherence 
barrier(s)63. Both models have been applied to medication 
adherence issues and were effective in identifying adherence 
barriers64-67.  
 
Further research is required to elucidate whether using these 
models can improve adherence rates. It should focus on 
developing specific interventions that address individual 
adherence barriers, based on the domains of the models 
allowing individually tailored strategies to improve medicines 
adherence.  
 
Pharmacist Interventions 
 
A two-year RCT conducted in a hospital, to determine the 
effect of periodic adherence promoting telephone counselling 
by a pharmacist on mortality in patients receiving 
polypharmacy. Participants were deemed be non-adherent to 
their medications but otherwise stable. Of the 442 randomised 
patients, 236 became adherent. When conducting 
telephoneconsultations, pharmacists measured adherence using 
a questionnaire and had access to medicines information.The 
intervention group had fewer non-adherent patients who 
remained non-adherent plus adherent patients that remained 
adherent. This intervention reduced the risk of mortality by 6% 
(from 17% to 11%)68. A limitation of this study is that it’s 
difficult to prove mortality effect with this intervention alone; 
other factors could have contributed to the death of the 
participants.  
 
Elliott et al. studied the New Medicines Service (NMS) in 
England69. The service increased adherence rates by around 
10%, and increased the number of medication issues identified 
and resolved. In the short term, the service saved the NHS 
money on each patient included. Long term, the study 
suggested NMS would deliver improved patient outcomes at 
total reduced cost for the NHS.  
 
DISCUSSION 
 
This review focussed on the behaviour of individuals regarding 
adherence and how nonadherence arises in two categories; 
intentional and unintentional. Both categories demonstrate that 
within category, the level of adherence is still multifactorial. 
Consequently, nonadherence requires responses that are 
tailored to the individual cause. Patient nonadherence is due to 
many complex underlying issues, which can start off under the 
umbrella of unintentional nonadherence but manifest into a 
mixture of unintentional and intentional nonadherence. There 
is a need for further research into the relationship between 
intentional and unintentional nonadherence among different 
patient groups, conditions and types of treatment.  
 
This review looked at the effects of low adherence on health 
outcomes and on healthcare costs. Poor adherence has 
negatively effects health outcomes across differing diseases. 
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More research is required and ideally, be brought together 
address adherence issues across various disease states to be 
highlighted and addressed.  
 
Studies on the effect of low adherence on healthcare costs 
were reviewed. The published figures were approximations; no 
accurate figures were identified. However, the estimates still 
highlighted potentially huge financial burdens that 
nonadherence can have on healthcare costs. The NHS is 
currently required to make efficiency savings of £22 billion by 
2020/215. The estimates suggest potential savings could be 
considerable, but any implementation requires close 
monitoring to generate more accurate data. 
 
Finally, strategies to improve adherence rates were considered. 
Clearly studies show adherence to be an extremely complex 
topic and a ‘one size fits all solution’ approach is 
inappropriate. Understanding beliefs is crucial; healthcare 
professionals must understand how the patient views their 
medications to design tailored interventions. Both the TDF and 
COM-B frameworks have proven effective in identifying the 
root cause(s) of nonadherence. Research must focus on 
developing interventions that address individual barriers, based 
on the domains of these models. 
 
Limitations 
 
Several studies used had a relatively small number of 
participants. Indeed, Britten et al.(2003) and Fine and 
Worling(2001) both acknowledged sample size as a limitation.  
Further and larger studies are required10,35. 
 
A number of studies in this review had been carried out across 
many different countries. This can be both an advantage and 
disadvantage. The limitations are that causes of low adherence 
will differ between countries due to differences in 
demographics, healthcare systems, healthcare budgets etc. 
Reviews which use studies from one country or countries that 
have similar demographics and healthcare systems may be able 
to provide more insightful reasons as to why medicines 
nonadherence occurs.  
 
Any literature not written in English was not included in this 
review due to time and budget constraints.  More information 
would have been available if literature from other languages 
had been translated and analysed. However, by looking at the 
English abstracts for foreign language papers no significant 
issues were found to have been overlooked. 
 
CONCLUSION 
 
This review examined the various causes of medicines 
nonadherence and looked at the consequences poor adherence 
has on health and healthcare costs. Several interventions which 
showed promising results in improving adherence were 
highlighted. To conclude, this review highlights the need for 
further research to be commissioned in the following areas: 
 
 further understanding the relationship between 
intentional and unintentional nonadherence among 
different patient groups, conditions and types of 
treatment. 
 bringing together literature to allow adherence issues 
across various disease states to be highlighted and 
addressed. 
 further understanding patient beliefs about their 
medications. 
 having more accurate data on the financial cost 
medicines nonadherence has on healthcare systems. 
 further developing specific interventions that address 
individual adherence barriers by using behavioural 
change models (TDF and COM-B). 
 further looking into methods to improve integration 
between healthcare professions. 
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